Should low-dose (baby) aspirin be used for primary cardiovascular prevention in a 77-year-old man with hypertension, atherosclerotic disease, and chronic obstructive pulmonary disease?

Do Not Initiate Baby Aspirin for Primary Prevention in This 77-Year-Old Man

Low-dose aspirin should NOT be started for primary prevention in a 77-year-old man, even with hypertension, atherosclerosis, and COPD. The most recent high-quality evidence demonstrates that aspirin initiated in adults ≥60 years provides no net benefit and increases major bleeding risk, which outweighs any potential cardiovascular benefit 1, 2.

Key Clinical Reasoning

Age is the Critical Factor

The 2022 USPSTF guidelines explicitly recommend against initiating aspirin in adults ≥60 years for primary prevention (Grade D recommendation) 2. This represents a significant shift from older guidance and is based on:

• No mortality benefit: Extended follow-up from the ASPREE trial (2025) showed no long-term benefit for major adverse cardiovascular events in older adults, with a concerning trend toward higher MACE rates post-trial (HR 1.17) 3
• Increased bleeding risk: Major hemorrhage risk increased 24% over the entire study period (HR 1.24), with bleeding rates of 4-12 per 1000 older persons over 5 years 4, 3

The 2020 Hypertension Canada Guidelines Removed Aspirin Recommendation

Hypertension Canada explicitly removed their previous recommendation for aspirin in primary prevention after reviewing recent evidence 1. They concluded:

• The HOT trial showed only 15% reduction in cardiovascular events but 74% increase in major bleeds
• Recent trials (ASPREE, meta-analyses) demonstrate little overall effectiveness with significant bleeding risk
• "Aspirin is no longer recommended for primary prevention in individuals with hypertension" 1

Atherosclerosis Presence: A Critical Distinction

The question mentions "aorta atherosclerosis" - this requires clarification:

If this means established atherosclerotic cardiovascular disease (prior MI, stroke, revascularization):

• This would be secondary prevention, not primary prevention
• Aspirin IS strongly recommended for secondary prevention 5, 6

If this means imaging findings of atherosclerosis without clinical events:

• This remains primary prevention
• The 2022 ACC/AHA guidelines for aortic disease recommend aspirin only for atherosclerotic thoracic aortic aneurysm with concomitant aortic atheroma or penetrating aortic ulcer (Class IIa) 6
• Asymptomatic atherosclerosis alone does not justify aspirin in this age group

COPD Considerations

Recent 2025 data from ADAPTABLE trial showed no significant difference in outcomes between aspirin doses in patients with COPD, though there was a signal for increased stroke risk with lower doses 7. However, this was a secondary prevention study - it does not support initiating aspirin for primary prevention in COPD patients.

Bleeding Risk Assessment

At age 77, this patient faces substantially elevated bleeding risk:

• Older age is the strongest predictor of aspirin-related bleeding
• Estimated major GI bleeding: 4-12 per 1000 older persons over 5 years 4
• COPD may increase bleeding risk through multiple mechanisms (anticoagulation for pulmonary hypertension, chronic cough, potential bronchiectasis)

What Should Be Done Instead

Focus on proven primary prevention strategies:

1. Statin therapy: Strongly recommended for patients with ≥3 cardiovascular risk factors or established atherosclerotic disease (Grade A) 1

2. Blood pressure control: Target SBP <130 mmHg, DBP <80 mmHg using antihypertensive medications 1, 6

3. Smoking cessation: If applicable, with combination of counseling and pharmacotherapy 1

4. COPD optimization: Proper inhaler therapy and pulmonary rehabilitation

Common Pitfalls to Avoid

• Do not confuse primary and secondary prevention: If this patient has had a prior MI or stroke, aspirin IS indicated
• Do not use outdated guidelines: Pre-2019 guidelines often recommended aspirin more liberally in older adults
• Do not assume atherosclerosis on imaging = clinical ASCVD: Imaging findings alone don't change the primary prevention recommendation against aspirin in this age group
• Do not ignore the 2020 Hypertension Canada explicit removal of aspirin recommendations for hypertensive patients 1

The Evidence Evolution

The recommendation against aspirin in older adults represents a major shift based on three pivotal 2018-2019 trials and subsequent long-term follow-up:

• ASPREE (elderly): No benefit, increased bleeding and mortality 3, 8
• ASCEND (diabetes): Modest benefit offset by bleeding 5, 8
• ARRIVE (multiple risk factors): No benefit, increased bleeding 8

The 2019 ACC/AHA guidelines downgraded aspirin to Class IIb (may be considered) only for ages 40-70 at high risk, and noted the benefit-harm ratio has narrowed considerably 9. For adults >70 years, they state aspirin is "potentially harmful and difficult to justify" 9.